Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline
Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japanese market, management has undertaken an ambitious overhaul to diversify away from its stagnant local market and overcome patent expiries with acquisitions. In January 2019, it closed its purchase of Shire Plc for approximately $57 billion. The megadeal not only gave Takeda access to Shire’s rare-disease and plasma-derived therapies, but it also granted Takeda much greater penetration into US markets and diversification away from Japan’s cost-cutting policies.
United States